Factory 99% Sunitinib Powder CAS 557795-19-4 Chemical Intermediate Sunitinib

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: A510
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Name: Sunitinib
• CAS: 557795-19-4
• Appearance: White Powder
• Assay: 99%
• OEM: Available
• Sample: Available
• Suitable: Adult
• MOQ: 10g
• Function: Anti-Angiogenic
• Transport Package: Foil Bag
• Specification: 99
• Trademark: /
• Origin: China
• Production Capacity: 10000 Kgs Per Month

Product Description

Product Name	Sunitinib
Appearance	White Powder
CAS NO.	557795-19-4
Molecular Formula	C22H27FN4O2
Storage	Keep in a cool, dry, dark location

 

 

Sunitinib is a small-molecule drug that targets multiple receptor tyrosine kinases involved in tumor angiogenesis (blood vessel formation) and tumor cell proliferation. By inhibiting these kinases, sunitinib disrupts the blood supply to the tumor and slows its growth.

 

1. Renal Cell Carcinoma: Sunitinib is a first-line treatment option for patients with advanced or metastatic renal cell carcinoma.
2. Gastrointestinal Stromal Tumors: It is also used in the management of gastrointestinal stromal tumors (GIST) that have progressed or cannot be surgically removed.
3. Pancreatic Neuroendocrine Tumors: Sunitinib can be prescribed for the treatment of pancreatic neuroendocrine tumors (pNETs) in specific circumstances.

1. Anti-angiogenic Effects: By inhibiting vascular endothelial growth factor receptors (VEGFRs), sunitinib disrupts the formation of new blood vessels that feed the tumor.
2. Inhibition of Tumor Cell Proliferation: By blocking other tyrosine kinases such as platelet-derived growth factor receptors (PDGFRs) and stem cell factor receptor (KIT), sunitinib slows the growth and division of tumor cells.
3. Improvement of Survival Outcomes: In clinical trials, sunitinib has demonstrated improvements in progression-free survival and overall survival in patients with certain types of cancer.